The rise in multidrug resistant (MDR) organisms portends a serious global threat to the 26 healthcare system with nearly untreatable infectious diseases, including pneumonia and its often 27 fatal sequelae, acute respiratory distress syndrome (ARDS) and sepsis. Gram-negative bacteria 28 (GNB) including Acinetobacter baumannii, Pseudomonas aeruginosa, and carbapenemase-29 producing Klebsiella pneumoniae (CPKP), are among the World Health Organization and National 30 Institutes of Health's high priority MDR pathogens for targeted development of new therapies. Here 31
ABSTRACT 25
The rise in multidrug resistant (MDR) organisms portends a serious global threat to the 26 healthcare system with nearly untreatable infectious diseases, including pneumonia and its often 27 fatal sequelae, acute respiratory distress syndrome (ARDS) and sepsis. Gram-negative bacteria 28 we show that stabilizing the host's vasculature by genetic deletion or pharmacological inhibition 32 of the small GTPase ADP-ribosylation factor 6 (ARF6) increases survival rates of mice infected 33 with A. baumannii, P. aeruginosa, CPKP pneumonia. We show that pharmacological inhibition 34 of ARF6-GTP phenocopies endothelial-specific Arf6 disruption in enhancing survival of mice 35 with A. baumannii pneumonia, suggesting that inhibition is on target. Finally, we show that the 36 mechanism of protection elicited by these small molecule inhibitors is by restoration of vascular 37 integrity disrupted by GNB lipopolysaccharide (LPS) activation of TLR4/MyD88/ARNO/ARF6 38 pathway. By targeting the host's vasculature with small molecule inhibitors of ARF6 activation, 39
we circumvent microbial drug resistance and provide a potential alternative/adjunctive treatment 40 for emerging and re-emerging pathogens. 41 INTRODUCTION increases endothelial permeability (13, 15, 16) . We have shown that stabilizing the vasculature 70 by reducing ARF6 activity is an effective strategy for reversing pathology and increasing 71 survival rates in several preclinical models of inflammatory and vascular disease, including 72 arthritis (15), LPS-induced endotoxemia (13) , and diabetic retinopathy (16). Here, we show that 73 stabilizing the vasculature through pharmacological inhibition of ARF6 activation by small 74 molecules can increase survival rates and reduce pathology in preclinical models of MDR GNB 75 infections. 76
77

RESULTS AND DISCUSSION 78
Arf6 conditional knockout mice are resistant to A. baumannii pneumonia 79
We previously showed that mice infected with MDR A. baumannii die from endotoxemia 80 caused by LPS activation of Toll Like Receptor-4 (TLR4) since TLR4-deficient mice are 81 completely protected from A. baumannii bacteremia (17). We hypothesized that triggering of 82 TLR4 by LPS during A. baumannii infection leads to activation of ARF6, resulting in increased 83 virulence by compromising vascular integrity. To test this hypothesis, we compared the virulence 84 of A. baumannii HUMC1 (a strain resistant to all antibiotics except colistin) (18, 19) in wild-type 85 versus Arf6 conditional knockout mice using pulmonary infection. Arf6 conditional knockout 86 mice were significantly more resistant to A. baumannii pneumonia with 40% overall survival 87 after 21 days post infection versus 0% survival for mice carrying two active Arf6 alleles (Arf6 f/+ ) 88 ( Figure 1A) . In another study, Arf6 f/+ or Arf6 conditional knockout mice (Arf6 f/-; +/Tie2-cre) 89
were infected with A. baumannii via inhalation and sacrificed for lung bacterial burden 4 days 90 post infection. Arf6 knockout mice had ~1.5 log 10 lower A. baumannii burden than wild-type 91 mice ( Figure 1B) . Collectively, these studies suggest that disruption of endothelial cell ARF6 92 allows the mouse immune system the opportunity to clear A. baumannii infection. 93
To test whether enhanced resistance of Arf6 knockout mice to A. baumannii pneumonia is 94 due to enhanced vascular integrity of the lungs, we infected mice with A. baumannii as above 95 and 3 days later intravenously injected them with Evans blue dye to assess lung permeability. As 96 expected, Arf6 f/+ mice showed increased vascular permeability by ~25% when compared to Arf6 97 conditional knockout mice ( Figure 1C ). Histopathological examination of the lungs corroborated 98 the permeability results, with Arf6 f/+ mouse lungs demonstrating enhanced tissue edema with 99 extensive hemorrhage compared to Arf6 conditional knockout mice ( Figure 1D ).
101
ARF6 inhibitors are protective against murine bacterial pneumonia 102
Because ARF6 activation promotes virulence of A. baumannii, we hypothesized that 103 pharmacologic ARF6 inhibition could be used to target GNB infections by stabilizing the 104
vasculature. Thus, we tested whether pharmacologic inhibition of ARF6 could increase survival 105 of mice with MDR GNB pneumonia. Small molecule ARF6 inhibitors, NAV-2729, A6-4424, 106 and A6-5093 were evaluated for efficacy in treating murine pneumonia due to GNB. NAV-2729 107 (IC50 = 1.5 M) has been shown to have therapeutic benefit in alleviating animal models of 108 diabetic retinopathy (16). A6-5093 is a new highly soluble prodrug of A6-4424 designed to 109 enhance in vivo administration. When A6-5093 is administered in vivo, its lysyl group is rapidly 110 cleaved to produce A6-4424 (S1 Figure A) , an active ARF6 inhibitor with IC50 = 1.9 M (S1 111
Figure B-C). 112
Immunosuppressed mice were infected with aerosolized A. baumannii HUMC1 (a 113 virulent MDR strain of A. baumannii that immunocompetent mice are resistant to) (18, 19). Mice 114 were treated with: 1) 30 mg/kg of NAV-2729 or A6-4424 (both dissolved in DMA/PEG and the 115 dose chosen based on pharmacokinetic (PK) data (S1 Figure Figure 2A ). Although mice treated with A6-4424 had a median survival time similar to vehicle-121 treated mice, 21-day survival was 50% versus 5% in vehicle-treated mice. Interestingly, the 122 enhanced survival of mice seen with the ARF6 inhibitors far exceeded survival seen with the 123 current first-line therapy of colistin ( Figure 2A ). 124
We investigated if the survival benefit correlated with reduction of bacterial burden in the 125 lungs. Mice were infected and treated as above and sacrificed on Day 4 post infection. Mice 126 treated with NAV-2729 or A6-5093 had at least 1-log 10 reduction in lung bacterial burden 127 compared to vehicle-treated mice ( Figure 2B ). Since A. baumannii HUMC1 is colistin sensitive 128 (19), mice treated with colistin had a 2-log 10 reduction of lungs bacterial burden versus vehicle-129 treated mice and 1-log 10 reduction versus ARF6 inhibitors ( Figure 2B ). Thus, the decreased 130 efficacy of colistin in survival studies is likely attributable to its toxicity (20) . 131
We also evaluated the activity of A6-5093 against murine pneumonia caused by MDR P. 132 aeruginosa or CPKP. Mice infected with CPKP or P. aeruginosa and treated with A6-5093 had 133 70% and 45% 21-day survival rates versus 10% and 0% survival rates for vehicle-treated mice, 134 respectively ( Figure 2C and 2D). Collectively, these results confirm the protective activity of 135 ARF6 inhibitors against at least three MDR GNB, which are noted for causing HAI (21). 136
137
ARF6 inhibitors enhance vascular integrity without affecting inflammation 138
We investigated the mechanism by which ARF6 inhibitors protect from GNB infection. First, 139
we determined if any of our ARF6 inhibitors has a direct inhibitory or microbicidal effect on the 140 three MDR bacteria under study. We performed minimal inhibitory concentration testing of the 141 pathogen using either NAV-2729, A6-4424, or vehicle control. We observed no difference in A. 142 baumannii, CPKP, or P. aeruginosa growth even at concentrations of 156 µM (S2 Figure) , 143 thereby indicating that the in vivo protection is likely due to an effect of the inhibitors on the 144 host.
ARF6 activation leads to increased vascular permeability via internalization of the 146
adherens junction protein VE-cadherin (13, 15, 16) . Thus, we hypothesized that ARF6 inhibitors 147 protect mice from GNB infection by maintaining vascular integrity. To investigate this 148 possibility, we determined the effect of ARF6 inhibitors on in vivo organ permeability and the 149 inflammatory response to A. baumannii pneumonia. Mice with A. baumannii pneumonia had an 150 ~50% and 30% increase in lung and kidney permeability, respectively, when compared to 151 uninfected mice. Treatment with either NAV-2729 or A6-5093 reduced the A. baumannii-152 mediated vascular permeability of lungs and kidneys to levels seen with uninfected mice (Figure  153 3A). These results were corroborated by histological examination of lungs harvested from mice 154 infected with A. baumannii, which showed signs of pneumonia and tissue edema consistent with 155 increased vascular permeability. Lungs harvested from mice infected and treated with either 156 NAV-2729 or colistin showed more normal architecture with minimal to no signs of tissue 157 edema ( Figure 3B ). Necrobiosis was evident in spleens taken from A. baumannii-infected mice 158 without treatment or with those treated with colistin but not in spleens harvested from infected 159 mice and treated with NAV-2729 ( Figure 3B ). The observed necrosis in spleens from colistin-160 treated mice is likely attributable to toxicity of colistin (20) . 161
LPS-induced endotoxemia results in a robust immune response via TLR4-mediated NF-162
κB activation (17). To determine the effect of ARF6 inhibitors on the inflammatory immune 163 response to A. baumannii pneumonia, we infected immunosuppressed mice and treated them as 164 described above for 4 days. Mice were sacrificed and plasma and lungs were collected for 165 determination of inflammatory cytokines. Due to the immunosuppression, which results in ~9 166 days of leukopenia (22), only IL-6 was detectable. No differences in IL-6 levels were observed 167 in the lungs or plasma collected from vehicle-, NAV-2729-, or colistin-treated mice ( Figure 3C ).
Collectively, these results show that ARF6 inhibitors likely protect mice from A. baumannii 169 pneumonia by preserving vascular integrity without affecting the inflammatory immune 170 response. 171 172
Bacterial LPS induces vascular permeability via the MyD88/ARNO/ARF6-GTP pathway 173
Previously we showed that that TLR4 activation by LPS compromises vascular integrity via 174 activation of the MyD88/ARNO/ARF6 pathway (13) . It was also shown that lethality in mice 175 infected with A. baumannii is mainly determined by the ability of the bacteria to activate TLR-4 176 through shed LPS. We hypothesized that GNB induces vascular permeability by activation of 177 the MyD88/ARNO/ARF6 pathway through their LPS. To investigate this hypothesis, we studied 178 if A. baumanaii and its LPS induce HUVEC vascular permeability in vitro. The virulent A. 179 buamanii MDR HUMC1 and its cell-free supernatant (this strain sheds LPS (17)) induced 180 HUVEC permeability equivalent to permeability seen with commercially available E. coli LPS, 181 while the avirulent drug-sensitive strain ATCC 17978 cells and supernatant did not (this strain 182 does not shed LPS (17)) ( Figure 4A ). To confirm that the enhanced HUVEC permeability 183 observed following treatment with HUMC1 supernatant was due to LPS shedding, we removed 184 LPS using polymyxin B agarose prior to incubating HUVECs with the supernatant (S3 Figure) . 185
Removal of LPS from the HUMC1 supernatant reduced permeability to uninfected HUVECs 186 levels ( Figure 4A ), thus confirming the role of bacterial LPS in compromising vascular integrity. 187
Mice with a TLR4 mutation or TLR4 knockout mice are resistant to A. baumannii 188 infection (17). Thus, we hypothesized that blocking TLR4 would abrogate the ability of A. 189 baumannii to induce HUVEC permeability. Indeed, anti-TLR4 antibodies completely blocked 190 the ability of A. baumannii HUMC1 or its cell-free culture supernatant to induce HUVEC permeability ( Figure 4B ). Finally, by using ARF6-GTP pulldown assay ( Figure 4C ), we show 192 that A. baumannii activated HUVEC ARF6 and NAV-2729 or A6-4424 reversed this activation 193 and its sequelae of endothelial permeability ( Figure 4D ). Similarly, A6-5093 reduced CPKP-or 194 P. aeruginosa-induced HUVEC permeability (S4 Figure) . 
A. baumannii enhances HUVEC permeability by promoting internalization of VE-cadherin. 211
We previously showed that LPS compromises vascular integrity by disruption of adherens 212 junctions via internalization of VE-cadherin (13) . To investigate whether a similar mechanism might be driving vascular permeability during A. baumannii infection, A. baumannii HUMC1-214
infected HUVECs were incubated with or without NAV-2729 and then immunostained with VE-215 cadherin antibody without permeabilization. A. baumannii reduced VE-cadherin surface 216 expression at the cell-cell junctions ( Figure 6A ) and resulted in disrupting the monolayer by 217 25%. In contrast, addition of NAV-2729 to infected HUVECs preserved the surface expression 218 of VE-cadherin and maintained the integrity of the monolayer to levels similar to those seen with 219 uninfected HUVECs ( Figure 6A-C) . Thus, A. baumannii compromises vascular integrity by 220 causing VE-cadherin internalization subsequent to ARF6 activation. 221
Based on these data and previously published results (13) (14) (15) (16) , we propose a model of 222
MDR GNB virulence that relies on LPS binding to TLR4, which activates two independent 223 pathways that diverge at MyD88: 1) a pathway that activates a robust immune response via NF-224 κB, which is characterized by an increase in inflammatory cytokines; and 2) a pathway that 225 compromises vascular integrity via activation of ARF6 and internalization of VE-cadherin, 226 resulting in excessive vascular leak, tissue edema, organ failure, and death. ARF6 inhibitors 227 block vascular leak without affecting the LPS-induced inflammatory immune response, thereby 228 allowing the immune system to fight the infection (Figure 7) . 229
By using ARF6 inhibitors to target the vascular leak that often accompanies severe 230 infections, we have markedly increased survival rates in preclinical models of life-threatening 231 infections of GNB. A primary advantage of this approach is that vascular leak is a host response 232 to infection. Therefore, targeting it should not lead to antimicrobial resistance. This approach 233 may prove to be applicable to any infection that activates MyD88/ARF6 (e.g., Staphylococcus 234 aureus and fungal infections) (23, 24). Although our data show that monotherapy can have a 235 marked effect on survival, in practice it is more likely that such an approach would be used as an Conditional Arf6 knockout mice. C57BL/6 mice harboring the Arf6 f (Arf6 with flanking LoxP 250 sites (S5 Figure A) and Arf6alleles have previously been described (27). Endothelial-specific 251
Arf6 -/conditional knockout mice were generated by crossing Arf6 f/f mice with Pdgfb-creERT2 252 mice. Excision of the Arf6 f allele in mice carrying the Pdgfb-creERT2 transgene was 253 accomplished by a single intraperitoneal injection of P1 mice with 40 µL of 1 mg/mL Tamoxifen 254 in corn oil. Arf6 excision in endothelial cells was verified by isolating lung endothelial cells as 255 previously described (28) and performing a Western blot to assess ARF6 levels using anti-ARF6 256 antibody from Cell Signaling Technology (#3546) (S5 Figure B) . Infected mice treated with vehicle or those treated with 2.5 mg/kg of colistin given twice daily 265 (bid) acted as controls. All treatments continued daily for seven days. The primary endpoints 266 were time to moribundity. Secondary endpoints using organs harvested on Day +4 relative to 267 infection, included tissue bacterial burden by quantitative culturing, inflammatory response, and 268 histopathological examination using hematoxylin and eosin or Gram stain. 269
The inflammatory cytokine response (IL-1β, IL-6, and TNF-α) was determined using 270
Cytometric Bead Array (BD Biosciences) per the manufacturer's instructions. 271
Mouse organ permeability was determined by injecting Evans blue dye (EBD) (Sigma) 3 272 days after infection and harvested organs were processed as previously described (29, 30) . Biolabs) (13) . Protein level of GTP-bound ARF6 and total ARF6 in cell lysates was detected by 308
Western blot with an anti-ARF6 antibody (1:1000 in 5% milk) (Sigma). 309 310 HUVEC gene knockdown. HUVECs were trypsinized and resuspended in growth medium with 311 30 nM of siRNAs targeting MyD88 (SI00300909), ARNO (SI00061299), and ARF6 312 (SI02757286) using HiPerFect transfection reagent (Qiagen) (13) and incubated for 2 days at 313 37 o C. The transfection process was repeated once more. All-Stars negative control siRNA 314 (Qiagen) was used as a control. RNA from transfected HUVEC was isolated using RNeasy Plus 315
Mini Kit (Qiagen) after incubation for 4 h with or without A. baumannii HUMC1. cDNA was 316 synthesized using RETROscript Reverse Transcription kit (Thermo Fisher Scientific). qPCR 317 reaction was prepared with Taqman Gene expression assay probes (Thermo Fisher Scientific) 318
and TaqMan gene expression Master Mix (Thermo Fisher Scientific). The qPCR was carried out 319 with a thermal-cycling program as follows: initial denaturing step for 10 min at 95°C, followed 320 by 40 cycles of denaturing at 95°C for 15 s, and annealing/elongation at 60°C for 1 min. Human 321 18s rRNA gene probe (Hs00917508_m1) was used as a reference control. Real-time Probes of 322 targeted genes were Human ARF6 (Hs01922781_g1), MyD88 (Hs00851874_g1), and ARNO 323 (Hs00244669_m1). The comparative Ct method (ΔΔCT) was used for data analysis. 324 325 VE-cadherin expression by confocal microscopy. HUVECs were seeded on coverslips that had 326 been pre-coated with fibronectin in 24-well plates. HUVECs were incubated with A. baumannii 327 HUMC1 for 4 h with or without 50 µM of ARF6 inhibitor, and then washed twice with PBS, 328 fixed with 4% formaldehyde for 10 min. The cells were washed 4 times with PBS, and then 329 blocked with 300 µl 50% human AB-serum (Sigma) for 10 min at room temperature. Mouse monoclonal VE-Cadherin antibody (BD Biosciences, # 555661) was added to the HUVECs (2.5 331 µg/mL) and held overnight at 4°C. Next, HUVECs were washed with PBS, counter stained with 332 2 mg/mL Alexa Fluor® 594 F(ab')2 goat anti-mouse IgG (Thermo Fisher Scientific, 1:300 in 2% 333 human serum-PBS) for 1 h at room temperature. The cells were stained with 1 µg/mL Hoeschst 334 33342 (ThermoFisher) in PBS for 10 min. HUVECs were washed twice with distilled water, and 335 wet mounted on glass slides, before examining by confocal microscopy. 336 337 VE-Cadherin quantification by flow cytometry. HUVECs were seeded in 6-well plate 338 (Costar) pre-coated with fibronectin. HUVECs were incubated with A. baumannii HUMC1 for 4 339 h with or without 50 µM of ARF6 inhibitor, and then washed twice with PBS. HUVECs were 340 detached from the plate with cellStripper dissociation reagent (ThermoFisher) that had been 341 prewarmed at 37C for 10 min. M199 medium containing 20% FBS was added to each well and 342 the cells collected. HUVECs were centrifuged, washed with PBS, and then fixed with 0.5 ml of 343 4% formaldehyde at room temperature for 15 min. The fixed cells were washed with PBS, 344 blocked with 50% human AB-serum, and then incubated with 2.5 µg/ml mouse monoclonal VE-345 cadherin antibody (BD Biosciences, # 555661) overnight at 4°C. The next day, cells were 346 washed with PBS and then incubated with Alexa Fluor® 488F(ab')2 goat anti-mouse IgG 347 secondary (ThermoFisher) (1:300 in 2% human serum-PBS from a stock of 2 mg/ml) for 1 h at 348 This work was supported by the National Institutes of Health [R22-R33 AI119339 and R01 373 AI063503 to ASI; R01 HL077671 and R01 EY025342 to WZ; R01 HL130541, R01 AR064788, 374
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